Eidos Therapeutics

Protego Biopharma

This biotechnology company develops small molecule therapies for patients with systemic amyloid diseases and other protein misfolding disorders.

Protego

This clinical-stage biotechnology company develops small molecule therapies that stabilise proteins to treat amyloidosis and other protein misfolding diseases for patients with organ damage.

ATTR

ATTR develops small-molecule stabilisers to treat patients with transthyretin amyloidosis by preventing protein breakdown and subsequent harmful amyloid deposit formation in the body.

Immutrin

This biotechnology company develops antibody therapies to remove amyloid deposits and treat cardiomyopathy for patients with amyloidosis.

Edgewise Therapeutics

This biopharmaceutical company develops small molecule therapies for patients with serious cardiovascular diseases and musculoskeletal conditions like Duchenne and Becker muscular dystrophy.

Brano Therapeutics

This company develops small-molecule inhibitors to treat heart failure and metabolic dysfunction for patients with cardiovascular diseases.

Edgewise

This biopharmaceutical company develops oral small molecule therapies to treat patients with rare skeletal and cardiac muscle diseases.

Arrakis Therapeutics

This biopharmaceutical company develops oral, small-molecule medicines that target RNA to treat patients with cancer, cardiovascular conditions, neurodegeneration and rare genetic diseases.